- Home
- SYNX vs VYNE Comparison
SYNX vs VYNE Comparison
Compare SYNX & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYNX
- VYNE
- Stock Information
- Founded
- SYNX 2005
- VYNE 2003
- Country
- SYNX Israel
- VYNE United States
- Employees
- SYNX N/A
- VYNE N/A
- Industry
- SYNX
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- SYNX
- VYNE Health Care
- Exchange
- SYNX Nasdaq
- VYNE Nasdaq
- Market Cap
- SYNX 10.2M
- VYNE 11.7M
- IPO Year
- SYNX 2024
- VYNE 2018
- Fundamental
- Price
- SYNX $1.08
- VYNE $0.39
- Analyst Decision
- SYNX
- VYNE Hold
- Analyst Count
- SYNX 0
- VYNE 1
- Target Price
- SYNX N/A
- VYNE N/A
- AVG Volume (30 Days)
- SYNX 35.7K
- VYNE 1.5M
- Earning Date
- SYNX 09-26-2025
- VYNE 11-06-2025
- Dividend Yield
- SYNX N/A
- VYNE N/A
- EPS Growth
- SYNX N/A
- VYNE N/A
- EPS
- SYNX N/A
- VYNE N/A
- Revenue
- SYNX $6,003,000.00
- VYNE $524,000.00
- Revenue This Year
- SYNX $32.35
- VYNE N/A
- Revenue Next Year
- SYNX N/A
- VYNE N/A
- P/E Ratio
- SYNX N/A
- VYNE N/A
- Revenue Growth
- SYNX N/A
- VYNE 6.29
- 52 Week Low
- SYNX $1.00
- VYNE $0.28
- 52 Week High
- SYNX $6.49
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- SYNX 21.05
- VYNE 56.99
- Support Level
- SYNX $1.20
- VYNE $0.34
- Resistance Level
- SYNX $1.28
- VYNE $0.39
- Average True Range (ATR)
- SYNX 0.09
- VYNE 0.03
- MACD
- SYNX -0.04
- VYNE 0.00
- Stochastic Oscillator
- SYNX 3.70
- VYNE 77.76
About SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.